CNS Drugs

, Volume 21, Issue 5, pp 367–387

Atypical Antipsychotics for the Treatment of Bipolar Disorder

More Shadows than Lights
Review Article

Abstract

Atypical antipsychotics are utilised more frequently for the treatment of bipolar disorder than first-generation antipsychotics because of their improved neurological tolerability. Furthermore, recent studies suggest that psychiatric outcomes are improved in patients treated with atypical agents. The aim of this article is to review the studies evaluating the effectiveness of atypical antipsychotics in treating acute bipolar episodes (bipolar mania, bipolar depression and mixed episodes), as well as those investigating the effectiveness of atypical antipsychotics as maintenance treatment for the disorder.

Because of several relevant methodological limitations affecting the vast majority of clinical trials, evidence-based information about the effectiveness of atypical antipsychotics in treating bipolar disorder is somewhat discouraging. Moreover, data indicating effectiveness in managing the acute manic phase and in long-term maintenance treatment are quantitatively robust only for olanzapine. However, olanzapine seems to have no advantages in terms of tolerability and therapy compliance when compared with classical mood stabilisers or first-generation antipsychotics. In addition, only a few studies have investigated the efficacy of atypical antipsychotics for treating bipolar depression. Hence, information regarding the effectiveness of such medications in treating this specific phase of bipolar disorder should be considered as still preliminary.

Given this situation, further independent and well-designed studies are urgently needed before definitive conclusions on the effectiveness of most atypical antipsychotics in the different clinical situations characterising the natural course of bipolar disorder can be drawn.

References

  1. 1.
    World Health Organization. World health report. Mental health: new understanding, new hope. Geneva: World Health Organization, 2001Google Scholar
  2. 2.
    Swann A. Practical management of depressive and manic episodes. In: Garza-Trevino ES, ed. Medical psychiatry: theory and practice. Vol. 1. Teaneck (NJ). World Scientific, 1989Google Scholar
  3. 3.
    Harma BJ, Nasrallah HA, Clancy J, et al. Psychiatric diagnosis and risk for tardive dyskinesia. Arch Gen Psychiatry 1993; 40: 346–7Google Scholar
  4. 4.
    Cavazzoni P, Berg PH, Kryhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006; 67: 107–13PubMedCrossRefGoogle Scholar
  5. 5.
    Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br J Psychiatry 1995; 166: 375–81CrossRefGoogle Scholar
  6. 6.
    Keck Jr PE, McElroy SL. Redefining mood stabilization. J Affect Dis 2003; 73: 163–9PubMedCrossRefGoogle Scholar
  7. 7.
    CenterWatch, Clinical Trials Listing Service™. Drugs approved by the FDA [online]. Available from URL: http://www.centerwatch.com/patient/drugs/dru545.html [Accessed 2006 May 1]
  8. 8.
    Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88PubMedCrossRefGoogle Scholar
  9. 9.
    Swann AC, Secunda SK, Katz MM, et al. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. Psychiatr Res 1986; 118: 127–41CrossRefGoogle Scholar
  10. 10.
    Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981; 64: 226–37PubMedCrossRefGoogle Scholar
  11. 11.
    Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986; 148: 723–5PubMedCrossRefGoogle Scholar
  12. 12.
    Judd L, Akiskal H, Schletter P, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530–7PubMedCrossRefGoogle Scholar
  13. 13.
    Zarate Jr CA. Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000; 61Suppl. 8: 52–61PubMedGoogle Scholar
  14. 14.
    Miller DS, Latham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry 2001; 62(12): 975–80PubMedCrossRefGoogle Scholar
  15. 15.
    Gentile S. Long-term atypical antipsychotic treatment and risk of weight gain: a literature analysis. Drug Saf 2006; 29(4): 303–19PubMedCrossRefGoogle Scholar
  16. 16.
    Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195–212PubMedCrossRefGoogle Scholar
  17. 17.
    Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring, and management. Bipol Disord 2003; 5Suppl. 2: 62–79CrossRefGoogle Scholar
  18. 18.
    Gentile S. Antipsychotic-associated weight gain [letter]. Ann Pharmacother 2004; 38: 903PubMedGoogle Scholar
  19. 19.
    Guille C, Sachs G, Ghaemi S. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61: 638–42PubMedCrossRefGoogle Scholar
  20. 20.
    Liebermann JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353(12): 1209–23CrossRefGoogle Scholar
  21. 21.
    Zyprexa (olanzapine) tablets and Zyprexa Zydis (olanzapine) orally disintegrating tablets (prescribing information). Indianapolis (IN): Eli Lilly and Company, 2004Google Scholar
  22. 22.
    Abilify (aripiprazole) tablets and oral solution (prescribing information). Princeton (NJ): Bristol-Myers Squibb Company, 2005; Rockville (MD): Otsuka America Pharmaceutical, Inc., 2005Google Scholar
  23. 23.
    Department of Health and Human Services, Public Health Service, Food and Drug Administration. Supplemental new drug (Seroquel®) application. Rockville (MD): Department of Health and Human Services, 2006 Oct 20Google Scholar
  24. 24.
    Padala PR, Wengel SP, Petty F. Manic episode during treatment with aripiprazole [letter]. Am J Psychiatry 2007; 164(1): 172–3PubMedCrossRefGoogle Scholar
  25. 25.
    Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebocontrolled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651–8PubMedCrossRefGoogle Scholar
  26. 26.
    Keck Jr PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626–37PubMedCrossRefGoogle Scholar
  27. 27.
    Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole in acute bipolar mania. Br J Psychiatry 2005; 187: 235–42PubMedCrossRefGoogle Scholar
  28. 28.
    Lykouras L, Gournellis R, Angelopoulos E. Manic symptoms induced by olanzapine. Eur Neuropsychopharmacol 2001; 11(2): 97–8PubMedCrossRefGoogle Scholar
  29. 29.
    Benazzi F. Olanzapine-induced psychotic mania in bipolar schizo-affective disorder. Eur Psychiatry 1999; 14(7): 410–1PubMedCrossRefGoogle Scholar
  30. 30.
    Simon AE, Aubry JM, Malky L, et al. Hypomania-like syndrome induced by olanzapine. Int Clin Psychopharmacol 1999; 14(6): 377–8PubMedCrossRefGoogle Scholar
  31. 31.
    Fitz-Gerald MJ, Pinkofsky HB, Brannon G, et al. Olanzapineinduced mania [letter]. Am J Psychiatry 1999; 156: 1114PubMedGoogle Scholar
  32. 32.
    Pozo P, Alcantara AG. Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment. J Psychiatry Neurosci 1988; 23(5): 309–10Google Scholar
  33. 33.
    Reeves RR, McBride WA, Brannon GE. Olanzapine-induced mania. J Am Osteopath Assoc 1998; 98(10): 549–50PubMedGoogle Scholar
  34. 34.
    Lyndenmayer JP, Klebanov R. Olanzapine-induced manic-like syndrome. J Clin Psychiatry 1998; 59(6): 318–9CrossRefGoogle Scholar
  35. 35.
    London JA. Mania associated with olanzapine. J Am Acad Child Adolesc Psychiatry 1998; 37(2): 135–6PubMedCrossRefGoogle Scholar
  36. 36.
    Henry C, Demoted-Mainard J. Olanzapine-induced mania in bipolar disorder [letter]. Rev Psychiatr Neurosci 2002; 27(3): 200Google Scholar
  37. 37.
    Fahy S, Fahy T. Induction of manic symptoms by novel antipsychotics [letter]. Br J Psychiatry 2000; 176: 597CrossRefGoogle Scholar
  38. 38.
    Narayan G, Puranik A. Olanzapine-induced mania. Int J Psychiatry Clin Pract 2000; 4: 333–4CrossRefGoogle Scholar
  39. 39.
    Tohen M, Ranger TM, McElroy SL, et al. Olanzapine versus placebo in treatment of acute mania. Am J Psychiatry 1999; 156: 702–9PubMedGoogle Scholar
  40. 40.
    Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000; 57: 841–9PubMedCrossRefGoogle Scholar
  41. 41.
    Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247–56PubMedCrossRefGoogle Scholar
  42. 42.
    Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–88PubMedCrossRefGoogle Scholar
  43. 43.
    Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar I and type II major depression: lack of manic induction. J Affect Dis 2005; 87: 121–30PubMedCrossRefGoogle Scholar
  44. 44.
    Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int J Clin Psychopharmacol 1999; 14: 339–43CrossRefGoogle Scholar
  45. 45.
    Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011–7PubMedCrossRefGoogle Scholar
  46. 46.
    Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62–9PubMedCrossRefGoogle Scholar
  47. 47.
    Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilisers v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337–45PubMedCrossRefGoogle Scholar
  48. 48.
    Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148–55PubMedCrossRefGoogle Scholar
  49. 49.
    Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025–33PubMedCrossRefGoogle Scholar
  50. 50.
    Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263–71PubMedCrossRefGoogle Scholar
  51. 51.
    Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281–9PubMedCrossRefGoogle Scholar
  52. 52.
    Tohen M, Goldberg JF, Gonzales-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60: 1218–26PubMedCrossRefGoogle Scholar
  53. 53.
    Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60PubMedCrossRefGoogle Scholar
  54. 54.
    Thase ME, MacFadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol 2006; 26(6): 600–9PubMedCrossRefGoogle Scholar
  55. 55.
    Delbello MP, Schwiers ML, Rosemberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1216–23PubMedCrossRefGoogle Scholar
  56. 56.
    Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004; 24(6): 599–606PubMedCrossRefGoogle Scholar
  57. 57.
    Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipol Disord 2004; 6: 213–33CrossRefGoogle Scholar
  58. 58.
    Mclntyre RM, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12 week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15(5): 573–85CrossRefGoogle Scholar
  59. 59.
    Bowden CL, Grunze H, Mullen J, et al. A randomised, double-blind, placebo-controlled efficacy of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66(1): 111–21PubMedCrossRefGoogle Scholar
  60. 60.
    Delbello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 1–9CrossRefGoogle Scholar
  61. 61.
    Atmaca M, Kuloglu M, Buyukbayram A, et al. Quetiapine-associated and dose-related hypomania in a woman with schizophrenia. Eur Psychiatry 2002; 17(5): 292–3PubMedCrossRefGoogle Scholar
  62. 62.
    Benazzi F. Quetiapine-associated hypomania in a woman with schizoaffective disorder. Can J Psychiatry 2001; 46(2): 182–3PubMedGoogle Scholar
  63. 63.
    Pacchiarotti I, Manfredi G, Kotzalidis GD, et al. Quetiapine-induced mania [letter]. Aust N Z J Psychiatry 2003; 37(5): 626PubMedGoogle Scholar
  64. 64.
    Lykouras L, Oulis P, Hatzimanolis J. Manic symptoms associated with quetiapine treatment. Eur Neuropsychopharmacol 2003; 13: 135–6PubMedCrossRefGoogle Scholar
  65. 65.
    Biancosino B, Marmai L, Facchi A, et al. Quetiapine may induce mania: a case report. Can J Psychiatry 2003; 48: 349–50PubMedGoogle Scholar
  66. 66.
    Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania. Br J Psychiatry 2005; 187: 229–34PubMedCrossRefGoogle Scholar
  67. 67.
    Hirschfeld RMA, Keck Jr PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057–65PubMedCrossRefGoogle Scholar
  68. 68.
    Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropsychopharmacol 1988; 21(3): 176–80Google Scholar
  69. 69.
    Sachs GS, Grossman F, Ghaemi SN, et al. Combination of mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146–54PubMedCrossRefGoogle Scholar
  70. 70.
    Yatham LN, Grossman F, Augustyns I, et al. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. Br J Psychiatry 2003; 182: 141–7PubMedCrossRefGoogle Scholar
  71. 71.
    Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsy-chopharmacol 2005; 15: 75–84CrossRefGoogle Scholar
  72. 72.
    Mithat B, Alpaslan T, Bulent C, et al. Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium: a case report. Pharmacopsychiatry 2005; 38: 105–6PubMedCrossRefGoogle Scholar
  73. 73.
    Guzelcan Y, de Haan L, Scholte WF. Risperidone may induce mania. Psychopharmacology (Berl) 2002; 126(1): 85–6Google Scholar
  74. 74.
    Zolezzi M, Badr MG. Risperidone-induced mania. Ann Pharmacother 1999; 33(3): 380–1PubMedCrossRefGoogle Scholar
  75. 75.
    Lane HY, Lin YC, Chang WH. Mania induced by risperidone: dose related? J Clin Psychiatry 1998; 59(2): 85–6PubMedCrossRefGoogle Scholar
  76. 76.
    Barkin JS, Pais Jr VM, Gaffney MF. Induction of mania by risperidone resistant to mood stabilizers. J Clin Psychopharmacol 1997; 17(1): 57–8PubMedCrossRefGoogle Scholar
  77. 77.
    Schnierow BJ, Graeber DA. Manic symptoms associated with initiation of risperidone. Am J Psychiatry 1996; 153(9): 1096–7Google Scholar
  78. 78.
    Tomlison WC. Risperidone and mania. Am J Psychiatry 1996; 153(1): 132–3Google Scholar
  79. 79.
    O’Croinin F, Zibin T, Holt L. Hypomania associated with risperidone [letter]. Can J Psychiatry 1995; 40(1): 51PubMedGoogle Scholar
  80. 80.
    Gopal S, Steffens DC, Kramer ML, et al. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005; 66(8): 1016–20PubMedCrossRefGoogle Scholar
  81. 81.
    Sundarajan V, Jainer AK. A mood stabilizer with risperidone or haloperidol for mania [letter]. Am J Psychiatry 2004; 161: 2139–40CrossRefGoogle Scholar
  82. 82.
    Lu BY, Lundgren R, Escalona PR, et al. A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry 2002; 63(12): 1185–6PubMedCrossRefGoogle Scholar
  83. 83.
    Davis R, Risch SC. Ziprasidone induction of hypomania in depression? Am J Psychiatry 2002; 195(4): 673–4CrossRefGoogle Scholar
  84. 84.
    Nolan BP, Schulte Jr JJ. Mania associated with initiation of ziprasidone [letter]. J Clin Psychiatry 2003; 64(3): 336PubMedCrossRefGoogle Scholar
  85. 85.
    Baldassano CF, Ballas C, Datto SM, et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipol Disord 2003; 5: 72–5CrossRefGoogle Scholar
  86. 86.
    Larson MF, Hauser A. Possible ziprasidone-induced mania. J Am Acad Child Adolesc Psychiatry 2003; 42: 1012–3PubMedCrossRefGoogle Scholar
  87. 87.
    Privitera MR, Maharaj K. Mania from dose-related augmentation of an SSRIs. J Clin Psychiatry 2003; 64: 1393–4PubMedCrossRefGoogle Scholar
  88. 88.
    Brieger P. Hypomanic episodes after receiving ziprasidone: an unintended “on-off-on” course of treatment [letter]. J Clin Psychiatry 2004; 65(1): 132PubMedCrossRefGoogle Scholar
  89. 89.
    Keating AM, Aoun SL, Dean CE. Ziprasidone-associated mania. Clin Neuropharmacol 2005; 28(2): 83–6PubMedCrossRefGoogle Scholar
  90. 90.
    Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741–8PubMedCrossRefGoogle Scholar
  91. 91.
    Potkin SG, Keck Jr PE, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebocontrolled replication trial. J Clin Psychopharmacol 2005; 25(4): 301–10PubMedCrossRefGoogle Scholar
  92. 92.
    Ross DE. Ziprasidone and mania [letter]. Am J Psychiatry 2004; 161(8): 1503PubMedCrossRefGoogle Scholar
  93. 93.
    Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289(4): 454–65PubMedCrossRefGoogle Scholar
  94. 94.
    Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med 2003; 78(8): 769–74PubMedCrossRefGoogle Scholar
  95. 95.
    Jagadheesan K, Muirhead D. Aripiprazole for acute bipolar mania. Am J Psychiatry 2004; 161(10): 1926–7PubMedCrossRefGoogle Scholar
  96. 96.
    Cipriani A, Rendell J, Geddes J. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006; 3: CD004362PubMedGoogle Scholar
  97. 97.
    Logue DD, Gonzalez N, Heligman SD, et al. Hyperglycemia in a 7-year-old child treated with aripiprazole. Am J Psychiatry 2007; 164(1): 173PubMedCrossRefGoogle Scholar
  98. 98.
    ECNP Newsletter. The use of placebo in clinical trials: a continuous debate [online]. Available from URL: http://ecnp.isite.nl/Matters/numberl/placebo.htm [Accessed 2007 Apr 2]
  99. 99.
    Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210–6PubMedCrossRefGoogle Scholar
  100. 100.
    Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007; 27(1): 35–45PubMedCrossRefGoogle Scholar
  101. 101.
    Yatham LM, Kennedy SH. Canadian Network for Mood and Anxiety Treatment (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipol Disord 2005; 7Suppl. 3: 5–69CrossRefGoogle Scholar
  102. 102.
    Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006; 85(1–3): 222–31PubMedCrossRefGoogle Scholar
  103. 103.
    McCue R, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189: 443–0Google Scholar
  104. 104.
    López-Mu>noz A, Vieta E, Rubio G, et al. Bipolar disorder as an emerging pathology in the scientific literature: a bibliometric approach. J Affect Dis 2006; 92: 161–70CrossRefGoogle Scholar
  105. 105.
    Rendell JM, Gijsman HJ, Keck P, et al. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003; (3): CD004040Google Scholar
  106. 106.
    Rendell JM, Gijsman HJ, Keck P, et al. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006; (1): CD004043Google Scholar
  107. 107.
    Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67(4): 509–16PubMedCrossRefGoogle Scholar
  108. 108.
    Gianfrancesco FD, Rajagopalan K, Sajatovic M, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 2006; 67(2): 222–32PubMedCrossRefGoogle Scholar
  109. 109.
    Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipol Disord 2006; 8: 232–41CrossRefGoogle Scholar
  110. 110.
    Kusumakar V, Yatham L, Haslam D, et al. Treatment of mania, mixed states, and rapid cycling. Can J Psychiatry 1997; 42Suppl. 2: S79–86Google Scholar
  111. 111.
    Bowden C, Brugger A, Swann A, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271: 918–24PubMedCrossRefGoogle Scholar
  112. 112.
    Rachid F, Bertschy G, Bondolfi G, et al. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004; 65(11): 1537–45PubMedCrossRefGoogle Scholar
  113. 113.
    Kahn DA, Sachs GS, Printz DJ, et al. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Pract 2000; 6: 197–211PubMedCrossRefGoogle Scholar
  114. 114.
    Olanzapine: prevention of bipolar disorder: unconvincing trials. Prescrire Int 2005; 14(78): 140–2Google Scholar
  115. 115.
    Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J Behav Health Serv Res 2005; 32(4): 438–45PubMedCrossRefGoogle Scholar
  116. 116.
    Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacother 2006; 26(8): 1134–47CrossRefGoogle Scholar
  117. 117.
    Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. A N Z J Psychiatry 2005; 39: 652–61CrossRefGoogle Scholar
  118. 118.
    Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149–73PubMedCrossRefGoogle Scholar
  119. 119.
    American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2004; 159: 1–50Google Scholar
  120. 120.
    Coppen A, Farmer R. Suicide mortality in patients on lithium maintenance therapy. J Affect Disord 1998; 50: 261–7PubMedCrossRefGoogle Scholar
  121. 121.
    Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8(2): 175–81PubMedCrossRefGoogle Scholar
  122. 122.
    Suppes T, Dennehy EB, Hirschfield RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. J Clin Psychiatry 2005; 66: 870–86PubMedCrossRefGoogle Scholar
  123. 123.
    Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipol Disord 2006; 8(3): 207–20CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Mental HealthOperative Unit n. 4, Mental Health Center n. 4SalernoItaly

Personalised recommendations